PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has announced the extension of its Single Ascending Dose study for Retinitis Pigmentosa type 11 into a multiple dose format with Institutional Review Board approval, enabling the collection of more comprehensive safety and efficacy data. The data from these studies will guide the design of a pivotal trial slated for 2025, potentially leading to the first approved treatment for RP11. This development could be a significant milestone for the company and patients suffering from this genetic eye disease.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
